A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

BE Houk, CL Bello, D Kang, M Amantea - Clinical Cancer Research, 2009 - AACR
Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for
advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal …
被引用次数：279 相关文章
[PDF] researchgate.net

[PDF][PDF] A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

BE Houk, CL Bello, D Kang, M Amantea - researchgate.net
Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for
advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal …
[PDF] academia.edu

[PDF][PDF] A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

BE Houk, CL Bello, D Kang, M Amantea - academia.edu
Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for
advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal …

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

BE Houk, CL Bello, D Kang… - … cancer research: an …, 2009 - pubmed.ncbi.nlm.nih.gov
Purpose Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for
advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal …

[引用][C] A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

BE HOUK, CL BELLO, D KANG… - … cancer research (Print …, 2009 - pascal-francis.inist.fr
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary
Metabolite (SU12662) in Healthy Volunteers and Oncology Patients CNRS Inist Pascal-Francis …

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

BE Houk, CL Bello, D Kang, M Amantea - Clinical Cancer Research, 2009 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Sunitinib malate is an oral
multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and …

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.

BE Houk, CL Bello, D Kang… - Clinical Cancer Research …, 2009 - europepmc.org
Purpose Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for
advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal …

[引用][C] A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

BE HOUK, CL BELLO, D KANG… - Clinical …, 2009 - American Association for Cancer …